Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MADRIGAL PHARMACEUTICALS, INC. Director's Dealing 2012

Mar 9, 2012

30608_dirs_2012-03-08_d47b4f06-4d8c-4346-9f16-ee71aec30048.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SYNTA PHARMACEUTICALS CORP (SNTA)
CIK: 0001157601
Period of Report: 2012-03-06

Reporting Person: Rieder Wendy E (VP, IP and Legal, Gen. Counsel)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-03-06 Employee Stock Option (Right to Buy) $4.22 A 48760 Acquired 2022-03-06 Common Stock (48760) Direct

Footnotes

F1: The option vests as to 25% of the shares on March 6, 2013 and as to an additional 6.25% of the shares on the last day of each successive three-month period thereafter.